Dr. Biernacka is a board-certified anatomic pathologist and cytopathologist with expertise in breast pathology. She works closely with other members of the Multidisciplinary Breast Program at the University of Chicago, providing comprehensive and coordinated care to breast cancer patients. Her clinical and research interests center on the morphologic and molecular features of breast diseases, with a special focus on apocrine lesions and androgen receptor signaling in breast cancer.
Massachusetts General Hospital
Fellowship - Breast Pathology
2017Dartmouth-Hitchcock
Fellowship - Cytopathology
2016Baylor College of Medicine
Residency - Anatomic Pathology
2015Albert Einstein College of Medicine
Postdoctoral Fellowship
2012The Medical University of Lodz
Poland
PhD
2012Anderson Cancer Center
MD
2010The Medical University of Lodz
Poland
MD
2006Fate of nondiagnostic thyroid fine needle aspirations.
Fate of nondiagnostic thyroid fine needle aspirations. Diagn Cytopathol. 2024 Dec; 52(12):709-714.
PMID: 39051543Cytomorphologic and molecular characterization of spindle cell carcinoid tumors of the lung.
Cytomorphologic and molecular characterization of spindle cell carcinoid tumors of the lung. Cancer Cytopathol. 2024 Oct; 132(10):656-665.
PMID: 39024046Lung adenocarcinomas with isolated TP53 mutation: A comprehensive clinical, cytopathologic and molecular characterization.
Lung adenocarcinomas with isolated TP53 mutation: A comprehensive clinical, cytopathologic and molecular characterization. Cancer Med. 2024 Jan; 13(1):e6873.
PMID: 38164123Exposure of Keratinocytes to Candida Albicans in the Context of Atopic Milieu Induces Changes in the Surface Glycosylation Pattern of Small Extracellular Vesicles to Enhance Their Propensity to Interact With Inhibitory Siglec Receptors.
Exposure of Keratinocytes to Candida Albicans in the Context of Atopic Milieu Induces Changes in the Surface Glycosylation Pattern of Small Extracellular Vesicles to Enhance Their Propensity to Interact With Inhibitory Siglec Receptors. Front Immunol. 2022; 13:884530.
PMID: 35784319Applications of nanodosimetry in particle therapy planning and beyond.
Applications of nanodosimetry in particle therapy planning and beyond. Phys Med Biol. 2021 12 10; 66(24).
PMID: 34731854Brain Tissue Low-Level Mosaicism for MTOR Mutation Causes Smith-Kingsmore Phenotype with Recurrent Hypoglycemia-A Novel Phenotype and a Further Proof for Testing of an Affected Tissue.
Brain Tissue Low-Level Mosaicism for MTOR Mutation Causes Smith-Kingsmore Phenotype with Recurrent Hypoglycemia-A Novel Phenotype and a Further Proof for Testing of an Affected Tissue. Diagnostics (Basel). 2021 Jul 15; 11(7).
PMID: 34359351Histopathologic and clinical outcomes of Milan System categories "non-diagnostic" and "non-neoplastic" of salivary gland fine needle aspirations.
Histopathologic and clinical outcomes of Milan System categories "non-diagnostic" and "non-neoplastic" of salivary gland fine needle aspirations. J Am Soc Cytopathol. 2021 Jul-Aug; 10(4):349-356.
PMID: 33867311Accuracy of Subclassification and Grading of Renal Tumors on Fine Needle Aspiration Cytology Alone.
Accuracy of Subclassification and Grading of Renal Tumors on Fine Needle Aspiration Cytology Alone. Acta Cytol. 2021; 65(2):140-149.
PMID: 33535202High-resolution, ultrasensitive and quantitative DNA double-strand break labeling in eukaryotic cells using i-BLESS.
High-resolution, ultrasensitive and quantitative DNA double-strand break labeling in eukaryotic cells using i-BLESS. Nat Protoc. 2021 02; 16(2):1034-1061.
PMID: 33349705Correction to: Feasibility Study of a Novel Protease-Activated Fluorescent Imaging System for Real-Time, Intraoperative Detection of Residual Breast Cancer in Breast Conserving Surgery.
View All Publications
Correction to: Feasibility Study of a Novel Protease-Activated Fluorescent Imaging System for Real-Time, Intraoperative Detection of Residual Breast Cancer in Breast Conserving Surgery. Ann Surg Oncol. 2020 Dec; 27(Suppl 3):967.
PMID: 32170477